In addition, arimoclomol was shown to be safe and well tolerated in a double-blind, placebo-controlled trial performed with rapidly progressive SOD1-mutant ALS patients (Benatar et al., 2018). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.